Evaluating the Efficacy of Paclitaxel in Reducing Neointimal Hyperplasia Following Peripheral Vascular Intervention

Background: Randomized trials in treating CLTI have demonstrated the effectiveness of paclitaxel-coated balloons (PCBs) in femoropopliteal disease. The article attempts to provide a survey of our observations concerning the paclitaxel-coated balloon to treat lesions in the femoropopliteal arteries. Methods: A single-arm trial was conducted involving 46 femoropopliteal lesions treated with PCB to gather data over an average follow-up period of two years. The endpoints assessed included primary patency at 12 months and late lumen loss (LLL) at 6 months and all-cause mortality at 12 months. Results: Technical success achieved 100%. The average lesion length is 107.1 ± 42 mm. The overall primary patency was 79.4% at one year. The mean late lumen loss was -0.35 mm, with a range of 0.07 to 0.51 mm. Conclusion: These findings indicate that the paclitaxel antimitotic drug is safe and effective for treating femoropopliteal artery disease. Keywords: Paclitaxel-coated balloon, Femoropopliteal artery, chronic limb-threatening ischemia